United StatesAurum Capital has launched its Investment-Driven Medical Innovation Initiative, aiming to expand research ...

“Stories of Hope” shares the stories of the people and scientists at the forefront of advancing medical science and pushing ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Breakthrough for prostate cancer patients as NHS now offers life-extending drug - The new medication is suitable for patients ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

It's a great opportunity to "buy low." ...

Drugmaker Cipla saw a 57 dip in net profit at ₹676 crore for the third quarter (Q3) ended December 31, 2025, due to a halt in production at its partner’s plant in Greece, following an inspection by ...

Thousands of men with advanced prostate cancer in England are set to benefit from a life-extending drug that can be taken at ...

GSK is set to buy Rapt Therapeutics in a $2.2 billion deal. AstraZeneca agreed to a $630 million pact to secure remaining rights to armored CAR-T from AbelZeta. Bristol Myers Squibb signed a deal with ...

Astellas' CEO said he doesn't want to make acquisitions simply to fill a revenue gap. Takeda is preparing for Trintellix's U.S. patent expiry with a round of layoffs. | Astellas CEO said he doesn't ...